dc.contributor.author | Antolin, AA | |
dc.contributor.author | Tym, JE | |
dc.contributor.author | Komianou, A | |
dc.contributor.author | Collins, I | |
dc.contributor.author | Workman, P | |
dc.contributor.author | Al-Lazikani, B | |
dc.date.accessioned | 2017-11-23T12:46:24Z | |
dc.date.issued | 2018-02-15 | |
dc.identifier.citation | Cell chemical biology, 2018, 25 (2), pp. 194 - 205.e5 | |
dc.identifier.issn | 2451-9456 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/940 | |
dc.identifier.eissn | 2451-9448 | |
dc.identifier.doi | 10.1016/j.chembiol.2017.11.004 | |
dc.description.abstract | Chemical probes are essential tools for understanding biological systems and for target validation, yet selecting probes for biomedical research is rarely based on objective assessment of all potential compounds. Here, we describe the Probe Miner: Chemical Probes Objective Assessment resource, capitalizing on the plethora of public medicinal chemistry data to empower quantitative, objective, data-driven evaluation of chemical probes. We assess >1.8 million compounds for their suitability as chemical tools against 2,220 human targets and dissect the biases and limitations encountered. Probe Miner represents a valuable resource to aid the identification of potential chemical probes, particularly when used alongside expert curation. | |
dc.format | Print-Electronic | |
dc.format.extent | 194 - 205.e5 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | CELL PRESS | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Molecular Probes | |
dc.subject | Chemistry, Pharmaceutical | |
dc.subject | Small Molecule Libraries | |
dc.title | Objective, Quantitative, Data-Driven Assessment of Chemical Probes. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-11-14 | |
rioxxterms.funder | The Institute of Cancer Research | |
rioxxterms.identifier.project | Unspecified | |
rioxxterms.versionofrecord | 10.1016/j.chembiol.2017.11.004 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-02 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cell chemical biology | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2 | |
pubs.publication-status | Published | |
pubs.volume | 25 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Computational Biology and Chemogenomics | |
icr.researchteam | Medicinal Chemistry 2 | |
dc.contributor.icrauthor | Komianou, Angeliki | |
dc.contributor.icrauthor | Collins, Ian | |
dc.contributor.icrauthor | Workman, Paul | |
dc.contributor.icrauthor | Al-Lazikani, Bissan | |